Affinity Asset Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

Affinity Asset Advisors’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-666,666	Closed	-$1.33M	–	108
2025 Q3	$1.33M	Buy	+666,666	New	+$1.17M	0.12%	81
2023 Q4	–	Sell	-335,068	Closed	-$1.04M	–	94
2023 Q3	$1.04M	Buy	335,068 +35,000	+12%	+$109K	0.29%	58
2023 Q2	$855K	Buy	300,068 +100,686	+50%	+$380K	0.3%	56
2023 Q1	$786K	Buy	199,382 +99,382	+99%	+$363K	0.26%	61
2022 Q4	$396K	Buy	+100,000	New	+$526K	0.16%	60

Other funds holding MIST

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Affinity Asset Advisors's MIST Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Milestone Pharmaceuticals (MIST) in Q4 2025, closing a stake of 666,666 shares — an estimated $1.33M sold.

Affinity Asset Advisors first reported a position in MIST in Q4 2022 and held it in 5 quarters. The position peaked at $1.33M in Q3 2025. 79 funds tracked by Wall St. Rank hold MIST as of Q4 2025.

Affinity Asset Advisors reported no remaining Milestone Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Affinity Asset Advisors sold 666,666 Milestone Pharmaceuticals shares in Q4 2025, an estimated $1.33M.
Affinity Asset Advisors first reported a position in Milestone Pharmaceuticals in Q4 2022 and held it in 5 quarters.
Affinity Asset Advisors's Milestone Pharmaceuticals position peaked at $1.33M in Q3 2025.
79 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.